Finch Therapeutics Group Inc
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in hu… Read more
Finch Therapeutics Group Inc (FNCH) - Total Assets
Latest total assets as of June 2024: $45.58 Million USD
Based on the latest financial reports, Finch Therapeutics Group Inc (FNCH) holds total assets worth $45.58 Million USD as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Finch Therapeutics Group Inc - Total Assets Trend (2019–2024)
This chart illustrates how Finch Therapeutics Group Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Finch Therapeutics Group Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Finch Therapeutics Group Inc's total assets of $45.58 Million consist of 21.6% current assets and 78.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Finch Therapeutics Group Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Finch Therapeutics Group Inc's current assets represent 21.6% of total assets in 2024, a decrease from 47.0% in 2019.
- Cash Position: Cash and equivalents constituted 20.6% of total assets in 2024, down from 40.7% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 48.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Finch Therapeutics Group Inc Competitors by Total Assets
Key competitors of Finch Therapeutics Group Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Finch Therapeutics Group Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Finch Therapeutics Group Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Finch Therapeutics Group Inc is currently not profitable relative to its asset base.
Finch Therapeutics Group Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.87 | 3.81 | 9.24 |
| Quick Ratio | 3.87 | 3.81 | 9.24 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $12.82 Million | $ 26.92 Million | $ 94.68 Million |
Finch Therapeutics Group Inc - Advanced Valuation Insights
This section examines the relationship between Finch Therapeutics Group Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.50 |
| Latest Market Cap to Assets Ratio | 0.42 |
| Asset Growth Rate (YoY) | -10.2% |
| Total Assets | $49.75 Million |
| Market Capitalization | $21.11 Million USD |
Valuation Analysis
Below Book Valuation: The market values Finch Therapeutics Group Inc's assets below their book value (0.42 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Finch Therapeutics Group Inc's assets decreased by 10.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Finch Therapeutics Group Inc (2019–2024)
The table below shows the annual total assets of Finch Therapeutics Group Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $49.75 Million | -10.15% |
| 2023-12-31 | $55.37 Million | -66.02% |
| 2022-12-31 | $162.94 Million | -27.70% |
| 2021-12-31 | $225.37 Million | +36.31% |
| 2020-12-31 | $165.34 Million | +59.64% |
| 2019-12-31 | $103.57 Million | -- |